RCM TECHNOLOGIES, INC. (RCMT) SEC Filings & Earnings Calls
EquiReason read 10 RCM TECHNOLOGIES, INC. SEC filings in the last 12 months. Latest: 8-K on 2026-08-31 — Compensation committee approved PSUs and RSUs for executive officers under equity compensation plan; routine compensatory arrangement..
Source: SEC EDGAR filings · figures as of 2026-07-04 · read by EquiReason
- Market cap
- 263.2M
- P/E TTM
- 16.1
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 9 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
13 Aug 202610-QRCM Technologies reported Q2 2026 results with 20% revenue growth and 29.5% net income growth, driven by Engineering fixed-fee projects and Healthcare staffing.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $94M | +20% y/y |
| Net income · Q2-2026 | $5M | +30% y/y |
| Operating cash flow · H1-2026 | $14M | +54% y/y |
| Free cash flow · H1-2026 | $13M | |
| Gross profit · Q2-2026 | $24M | +8% y/y |
| Engineering Fixed Fee Revenue · Engineering · Q2-2026 | $27M | +131% y/y |
| Specialty Health Care Revenue · Specialty Health Care · Q2-2026 | $45M | +5% y/y |
| Deferred Revenue · Q2-2026 | $8M |
Risks flagged
Customer Concentration
“During the twenty-six weeks ended July 4, 2026, the Company had three customers that exceeded 10% of consolidated revenue, two customers in the Company’s Specialty Health Care segment, representing 23.3% and 13.3% of consolidated revenue, respectively, and one customer in the Company’s Engineering segment, representing 13.5%.” · word for word
Deferred Revenue Decline
“Deferred revenue was $8.2 million as of July 4, 2026. Deferred revenue was $14.8 million as of January 3, 2026.”
14 May 202610-QRCMT reported Q1 2026 revenue of $83.0M, down 1.7% YoY, with mixed segment performance.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $83M | -2% y/y |
3 Apr 202610-KRCM Technologies reported FY2025 revenue of $319.4M (+14.7% YoY) and net income of $16.3M (+22.6% YoY), with strong growth in Engineering and Specialty Health Care, partially offset by LS&D decline and margin compression.earningsopen
Figures in the filing · each found in the filing text
| Revenue · FY2026 | $319M | +15% y/y |
| Net income · FY2026 | $16M | +23% y/y |
| Operating cash flow · FY2026 | $19M | +207% y/y |
| Free cash flow · FY2026 | $17M | |
| Gross profit · FY2026 | $88M | +10% y/y |
| Gross margin · FY2026 | 27.5% | |
| Adjusted EBITDA · FY2026 | $31M | +19% y/y |
| Specialty Health Care Revenue · Specialty Health Care · FY2026 | $164M | +15% y/y |
| Engineering Revenue · Engineering · FY2026 | $120M | +25% y/y |
| Life Sciences, Data and Solutions Revenue · Life Sciences, Data and Solutions · FY2026 | $35M | -11% y/y |
Risks flagged
Customer Concentration
“During the fiscal year ended January 3, 2026, the Company had two customers exceed 10% of consolidated revenue, representing 20.8% and 13.6% of consolidated revenue.” · word for word
Internal Control Weaknesses
“Management identified control deficiencies that resulted in material weaknesses in our internal control over financial reporting as of January 3, 2026.” · word for word
Geopolitical Risk (Serbia)
“Our operations in Serbia could be adversely affected by the current conflict between Ukraine and Russia, with which Serbia has substantial ties.” · word for word
Tariff Risk
“If significant tariffs or other restrictions are imposed or threatened on foreign businesses by the U.S., and affected countries take related countermeasures, our business and results of operations could be adversely affected.” · word for word
LS&D Revenue Decline
“Life Sciences, Data and Solutions revenue of $34.8 million for the fiscal year ended January 3, 2026, decreased 11.3%, or $4.4 million, compared to the comparable prior-year period.” · word for word
3 Apr 20268-K · 2.02FY2025 revenue $319.4M (+14.7% YoY), net income $16.3M (+22.6%), adjusted EBITDA $30.7M (+18.9%). Q4 revenue $86.5M (+12.4%), net income $6.1M (+112.9%). Strong growth across segments.earningsopen
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $319M | +15% y/y |
| Net income · FY2025 | $16M | +23% y/y |
| Adjusted EBITDA · FY2025 | $31M | +19% y/y |
| Diluted earnings per share · FY2025 | $2.14 | +27% y/y |
| Adjusted net income per diluted share · FY2025 | $2.50 | +23% y/y |
| Revenue · Q4-2025 | $86M | +12% y/y |
| Net income · Q4-2025 | $6M | +113% y/y |
| Adjusted EBITDA · Q4-2025 | $9M | +49% y/y |
| Diluted earnings per share · Q4-2025 | $0.80 | +116% y/y |
| Adjusted net income per diluted share · Q4-2025 | $0.77 | +57% y/y |
Risks flagged
No guidance provided; company not holding conference call, limiting forward visibility.
“Company will not be holding a conference call.” · word for word
13 Nov 2025DEF 14AProxy statement for annual meeting; no material event.open
Figures in the filing · each found in the filing text
| Net Income · FY2024 | $13M | |
| Adjusted EBITDA · FY2024 | $26M | |
| Total Shareholder Return (TSR) · FY2024 | $807.32 |
Risks flagged
Customer concentration risk
“DaVita represented 12% and 52% of net sales for the three months ended September 30, 2025 and 2024, respectively.”
Dependence on DaVita contract
“DaVita subsequently indicated that it will completely transition to another supplier... Discussions between Rockwell and DaVita are ongoing and include a potential contract extension and/or future volume commitments by DaVita to Rockwell. There can be no assurance that these discussions will yield a successful outcome for Rockwell.”
6 Nov 202510-QQ3 FY2025 revenue grew 16.4% YoY to $70.3M, but net income declined 17.7% to $2.3M due to margin compression and higher SG&Aearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $70M | +16% y/y |
| Revenue · FY2025 | $233M | +16% y/y |
| Net income · Q3-2025 | $2M | -18% y/y |
| Net income · FY2025 | $10M | -2% y/y |
| Operating cash flow · FY2025 | $8M | -4% y/y |
| Free cash flow · FY2025 | $6M | -2% y/y |
| Gross margin · Q3-2025 | 27.6% | |
| Adjusted EBITDA · Q3-2025 | $6M | -1% y/y |
| Adjusted EBITDA · FY2025 | $21M | +9% y/y |
| Adjusted diluted EPS · Q3-2025 | $0.42 | 0% y/y |
Risks flagged
Customer concentration
“During the thirty-nine weeks ended September 27, 2025, the Company had two customers exceed 10% of consolidated revenue, representing 19.6% and 13.2% of consolidated revenue, respectively.” · word for word
Gross margin pressure from mix shift
“The decrease in gross profit margin was primarily due to a change in mix associated with EPC project revenue from the Energy Services group and the increase in lower-margin Aerospace revenue.” · word for word
Liquidity risk from low cash balance
“Cash and cash equivalents at end of period $1,309” · word for word
High leverage / revolver dependence
“Borrowings under the line of credit as of September 27, 2025 and December 28, 2024 were $31.5 million and $35.0 million, respectively.” · word for word
5 Nov 20258-K · 2.02RCMT reported Q3 revenue of $70.3M (+16.4% YoY), gross profit $19.4M (+8.8%), GAAP net income $2.3M ($0.30/diluted share), adjusted EBITDA $5.5M. Record 2026 Engineering backlog and continued Healthcare momentum cited.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $70M | +16% y/y |
| Gross profit · Q3-2025 | $19M | +9% y/y |
| Adjusted EBITDA · Q3-2025 | $6M | -2% y/y |
| Diluted EPS (GAAP) · Q3-2025 | $0.30 | -14% y/y |
| Adjusted net income per diluted share · Q3-2025 | $0.42 | 0% y/y |
Risks flagged
Gross margin compression due to higher cost of services growth relative to revenue.
“Gross profit margin declined from 29.6% to 27.6%”
GAAP net income declined despite revenue growth, indicating margin pressure.
“Net income decreased from $2.7M to $2.3M”
RCM TECHNOLOGIES, INC. — questions
- What did RCM TECHNOLOGIES, INC. file recently?
- 10 SEC filings in the last 12 months. Latest: 8-K on 2026-08-31 — Compensation committee approved PSUs and RSUs for executive officers under equity compensation plan; routine compensatory arrangement.
Every figure on this page comes from RCM TECHNOLOGIES, INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.